

Medicore Medical Services Limited
Abridged Unaudited Financial Statements
for the financial year ended 31 March 2025

Medicare Medical Services Limited

CONTENTS

	Page
Directors' Responsibilities Statement	3
Balance Sheet	4 - 5
Statement of Changes in Equity	6
Notes to the Financial Statements	7 - 10

Medicore Medical Services Limited

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 March 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

David Bradley
Director

Doreen Bradley
Director

20 February 2026

Medicore Medical Services Limited

BALANCE SHEET

as at 31 March 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	6	158,056	24,044
Investments		84,807	84,807
		<u>242,863</u>	<u>108,851</u>
Current Assets			
Debtors	7	342,107	421,738
Cash and cash equivalents		362,119	54,811
		<u>704,226</u>	<u>476,549</u>
Creditors: amounts falling due within one year	8	<u>(247,465)</u>	<u>(195,877)</u>
Net Current Assets		<u>456,761</u>	<u>280,672</u>
Total Assets less Current Liabilities		699,624	389,523
Creditors:			
amounts falling due after more than one year	9	<u>(116,828)</u>	<u>(52,957)</u>
Net Assets		<u><u>582,796</u></u>	<u><u>336,566</u></u>
Capital and Reserves			
Called up share capital presented as equity		100	100
Retained earnings		582,696	336,466
Equity attributable to owners of the company		<u><u>582,796</u></u>	<u><u>336,566</u></u>

Medicore Medical Services Limited

BALANCE SHEET

as at 31 March 2025

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Medicore Medical Services Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 20 February 2026 and signed on its behalf by:

David Bradley
Director

Doreen Bradley
Director

Medicore Medical Services Limited
STATEMENT OF CHANGES IN EQUITY

as at 31 March 2025

	Called up share capital €	Retained earnings €	Total €
At 1 April 2023	100	300,373	300,473
Profit for the financial year	-	36,093	36,093
At 31 March 2024	100	336,466	336,566
Profit for the financial year	-	246,230	246,230
At 31 March 2025	100	582,696	582,796

Medicore Medical Services Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

1. General Information

Medicore Medical Services Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 454503. The registered office of the company is , J2 Rosemount Business Park, Dublin 11, Dublin, Ireland which is also the principal place of business of the company. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 31 March 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280B of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Consolidated accounts

The company is entitled to the exemption provided for in section 293 (1A) of the Companies Act 2014 from the obligation to prepare group accounts because it qualifies as a small company in accordance with the small companies' regime.

Turnover

Income from Ambulances Services, Event Medical Cover and Training is recognised when the service is delivered, and the company is confident that it will receive the consideration from the customer.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	15% Straight line
Motor vehicles	-	25% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Leasing and hire purchases

Tangible assets held under leasing and Hire Purchases arrangements which transfer substantially all the risks and rewards of ownership to the company are capitalised and included in the Balance Sheet at their cost or valuation, less depreciation. The corresponding commitments are recorded as liabilities. Payments in respect of these obligations are treated as consisting of capital and interest elements, with interest charged to the Profit and Loss Account.

Investments

Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related withholding tax is recognised in the profit and loss account in the financial year in which it is receivable.

Medicore Medical Services Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

Trade and other debtors

Trade and other debtors are recognised at the selling price less impairment losses for bad and doubtful debts.

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Trade and other creditors

Trade and other creditors are recognised at cost and are not discounted as the effect of discounting would be immaterial.

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Operating profit	2025	2024
	€	€
Operating profit is stated after charging:		
Depreciation of tangible assets	42,990	70,333
	<u> </u>	<u> </u>
4. Interest payable and similar expenses	2025	2024
	€	€
Interest	4,943	6,845
	<u> </u>	<u> </u>

5. Employees

The average monthly number of employees, including directors, during the financial year was 47, (2024 - 27).

Medicore Medical Services Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

6. Tangible assets	Fixtures, fittings and equipment €	Motor vehicles €	Total €
Cost			
At 1 April 2024	34,293	345,568	379,861
Additions	-	177,002	177,002
At 31 March 2025	<u>34,293</u>	<u>522,570</u>	<u>556,863</u>
Depreciation			
At 1 April 2024	27,534	328,283	355,817
Charge for the financial year	1,219	41,771	42,990
At 31 March 2025	<u>28,753</u>	<u>370,054</u>	<u>398,807</u>
Net book value			
At 31 March 2025	<u>5,540</u>	<u>152,516</u>	<u>158,056</u>
At 31 March 2024	<u>6,759</u>	<u>17,285</u>	<u>24,044</u>
7. Debtors		2025	2024
		€	€
Trade debtors		276,417	226,020
Amounts owed by group undertakings		65,690	195,718
		<u>342,107</u>	<u>421,738</u>
8. Creditors		2025	2024
Amounts falling due within one year		€	€
Amounts owed to credit institutions		44,696	16,036
Net obligations under finance leases and hire purchase contracts		18,584	27,152
Trade creditors		24,190	21,692
Taxation		153,255	125,465
Other creditors		1,492	284
Accruals		5,248	5,248
		<u>247,465</u>	<u>195,877</u>

Medicore Medical Services Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

9. Creditors	2025	2024
Amounts falling due after more than one year	€	€
Bank loan	116,828	37,792
Finance leases and hire purchase contracts	-	15,165
	<u>116,828</u>	<u>52,957</u>
Loans		
Repayable in one year or less, or on demand	44,696	16,036
Repayable between one and two years	44,694	32,072
Repayable between two and five years	72,134	5,720
	<u>161,524</u>	<u>53,828</u>
Net obligations under finance leases and hire purchase contracts		
Repayable within one year	18,584	27,152
Repayable between one and five years	-	15,165
	<u>18,584</u>	<u>42,317</u>
10. Income Statement	2025	2024
	€	€
At 1 April 2024	336,466	300,373
Profit for the financial year	246,230	36,093
	<u>582,696</u>	<u>336,466</u>
11. Capital commitments		
The company had no material capital commitments at the financial year-ended 31 March 2025.		
12. Directors' remuneration	2025	2024
	€	€
Remuneration	37,064	37,503
	<u>37,064</u>	<u>37,503</u>
13. Related party transactions		
The company has availed of the exemption under FRS 102 Section 1A in relation to the disclosure of transactions with group undertakings.		
14. Post-Balance Sheet Events		
There have been no significant events affecting the company since the financial year-end.		
15. Approval of financial statements		
The financial statements were approved and authorised for issue by the board of directors on 20 February 2026.		